HC Wainwright Issues Positive Forecast for Cardiff Oncology (NASDAQ:CRDF) Stock Price

Cardiff Oncology (NASDAQ:CRDF) had its target price lifted by equities researchers at HC Wainwright from $13.00 to $17.00 in a report issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target would suggest a potential upside of 318.72% from the company’s previous close.

Separately, Piper Sandler increased their price target on shares of Cardiff Oncology from $7.00 to $10.00 and gave the company an “overweight” rating in a research note on Friday, December 13th.

Cardiff Oncology Trading Down 9.0 %

NASDAQ CRDF opened at $4.06 on Friday. Cardiff Oncology has a 12 month low of $1.74 and a 12 month high of $6.42. The stock has a 50 day moving average of $4.06 and a 200-day moving average of $3.22. The company has a market cap of $207.60 million, a PE ratio of -4.32 and a beta of 1.77.

Insider Buying and Selling at Cardiff Oncology

In related news, Director Gary W. Pace acquired 350,115 shares of Cardiff Oncology stock in a transaction on Wednesday, December 11th. The stock was purchased at an average cost of $2.60 per share, with a total value of $910,299.00. Following the completion of the transaction, the director now directly owns 1,047,876 shares in the company, valued at $2,724,477.60. This trade represents a 50.18 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 7.60% of the company’s stock.

Institutional Trading of Cardiff Oncology

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Orbimed Advisors LLC bought a new stake in shares of Cardiff Oncology during the fourth quarter worth approximately $6,677,000. Acorn Capital Advisors LLC acquired a new stake in Cardiff Oncology during the 4th quarter worth approximately $6,260,000. Adage Capital Partners GP L.L.C. bought a new stake in Cardiff Oncology in the 4th quarter valued at $5,609,000. Laurion Capital Management LP acquired a new position in Cardiff Oncology in the 4th quarter valued at $2,504,000. Finally, Point72 Asset Management L.P. bought a new position in Cardiff Oncology during the 4th quarter worth $2,207,000. Institutional investors own 16.29% of the company’s stock.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.